[1] WHO Classification of Tumours Editorial Board. Breast tumours  [M]. 5th ed. Lyon: International Agency for Research on  Cancer, 2019.
[2] NCCN Clinical Practice Guideline in OncologyTM. Breast  Cancer. 2014 National Comprehensive Cancer Network[EB/  OL]. https://www.nccn.org/guidelines/nccn-guidelines/  guidelines-detail?category = 1&id = 1419[2021-09-02].
[3] American Joint Committee on Cancer. AJCC cancer staging  handbook[M]. 7th ed. Chicago: Springer, 2010.
[4] BUCHHOLZ T A, SOMERFIELD M R, GRIGGS J J, et al.  Margins for breast-conserving surgery with whole-breast  irradiation in stage I and II invasive breast cancer: American  Society of Clinical Oncology endorsement of the Society of  Surgical Oncology/American Society for Radiation Oncology  consensus guideline[J]. J Clin Oncol, 2014, 32(14): 15021506.
[5] KUNKLER I H, WILLIAMS L J, JACK W J, et al. Breastconserving surgery with or without irradiation in women aged  65 years or older with early breast cancer (PRIME II): a  randomised controlled trial[J]. Lancet Oncol, 2015, 16(3):  266-273.
[6] GIULIANO A E, MCCALL L, BEITSCH P, et al. Locoregional  recurrence after sentinel lymph node dissection with or without  axillary dissection in patients with sentinel lymph node  metastases: the American College of Surgeons Oncology Group  Z0011 randomized trial[J]. Ann Surg, 2010, 252(3): 426432; discussion 432-433.
[7] DONKER M, VAN TIENHOVEN G, STRAVER M E, et al.  Radiotherapy or surgery of the axilla after a positive sentinel  node in breast cancer (EORTC 10981-22023 AMAROS): a  randomised, multicentre, open-label, phase 3 non-inferiority  trial[J]. Lancet Oncol, 2014, 15(12): 1303-1310.
[8] MORAN M S, SCHNITT S J, GIULIANO A E, et al. Society of  Surgical Oncology-American Society for Radiation Oncology  consensus guideline on margins for breast-conserving surgery  with whole-breast irradiation in stages I and II invasive  breast cancer[J]. J Clin Oncol, 2014, 32(14): 1507-1515.
[9] EARLY BREAST CANCER TRIALISTS' COLLABORATIVE  GROUP (EBCTCG). Long-term outcomes for neoadjuvant  versus adjuvant chemotherapy in early breast cancer: metaanalysis of individual patient data from ten randomised trials  [J]. Lancet Oncol, 2018, 19(1): 27-39.
[10] GIANNI L, PIENKOWSKI T, IM Y H, et al. 5-year analysis  of neoadjuvant pertuzumab and trastuzumab in patients with  locally advanced, inflammatory, or early-stage HER2-positive  breast cancer (NeoSphere): a multicentre, open-label, phase 2  randomised trial[J]. Lancet Oncol, 2016, 17(6): 791-800.
[11] SIKOV W M, BERRY D A, PEROU C M, et al. Impact of the  addition of carboplatin and/or bevacizumab to neoadjuvant  once-per-week paclitaxel followed by dose-dense doxorubicin  and cyclophosphamide on pathologic complete response rates  in stage II to III triple-negative breast cancer: CALGB 40603  (Alliance)[J]. J Clin Oncol, 2015, 33(1): 13-21.
[12] ADAMS S, LOI S, TOPPMEYER D, et al. Pembrolizumab  monotherapy for previously untreated, PD-L1-positive,  metastatic triple-negative breast cancer: cohort B of the phase  II KEYNOTE-086 study[J]. Ann Oncol, 2019, 30(3): 405411.
[13] ADAMS S, SCHMID P, RUGO H S, et al. Pembrolizumab  monotherapy for previously treated metastatic triple-negative  breast cancer: cohort A of the phase II KEYNOTE-086 study  [J]. Ann Oncol, 2019, 30(3): 397-404.
[14] GOETZ M P, TOI M, CAMPONE M, et al. MONARCH 3:  abemaciclib as initial therapy for advanced breast cancer[J].  J Clin Oncol, 2017, 35(32): 3638-3646.
[15] ROBSON M, IM S A, SENKUS E, et al. Olaparib for metastatic  breast cancer in patients with a germline BRCA mutation[J].  N Engl J Med, 2017, 377(6): 523-533.
[16] SLEDGE G W Jr, TOI M, NEVEN P, et al. MONARCH 2:  abemaciclib in combination with fulvestrant in women with  HR+/HER2- advanced breast cancer who had progressed while  receiving endocrine therapy[J]. J Clin Oncol, 2017, 35(25):  2875-2884.
[17] SCHMID P, ADAMS S, RUGO H S, et al. Atezolizumab and  nab-paclitaxel in advanced triple-negative breast cancer[J].N Engl J Med, 2018, 379(22): 2108-2121.
[18] TRIPATHY D, IM S A, COLLEONI M, et al. Ribociclib plus  endocrine therapy for premenopausal women with hormonereceptor-positive, advanced breast cancer (MONALEESA-7):  a randomised phase 3 trial[J]. Lancet Oncol, 2018, 19(7):  904-915.
[19] TURNER N C, SLAMON D J, RO J, et al. Overall survival with  palbociclib and fulvestrant in advanced breast cancer[J]. N  Engl J Med, 2018, 379(20): 1926-1936.
[20] B L O K E J , K R O E P J R , M E E R S H O E K - K L E I N  KRANENBARG E, et al. Optimal duration of extended adjuvant  endocrine therapy for early breast cancer; results of the IDEAL  trial (BOOG 2006-05)[J]. J Natl Cancer Inst, 2018, 110(1).
[21] BURSTEIN H J, LACCHETTI C, ANDERSON H, et al.  Adjuvant endocrine therapy for women with hormone receptorpositive breast cancer: ASCO clinical practice guideline focused  update[J]. J Clin Oncol, 2019, 37(5): 423-438.
[22] FRANCIS P A, PAGANI O, FLEMING G F, et al. Tailoring  adjuvant endocrine therapy for premenopausal breast cancer  [J]. N Engl J Med, 2018, 379(2): 122-137.
[23] GNANT M, MLINERITSCH B, STOEGER H, et al. Zoledronic  acid combined with adjuvant endocrine therapy of tamoxifen  versus anastrozol plus ovarian function suppression in  premenopausal early breast cancer: final analysis of the Austrian  Breast and Colorectal Cancer Study Group trial 12[J]. Ann  Oncol, 2015, 26(2): 313-320.
[24] MAMOUNAS E P, BANDOS H, LEMBERSKY B C, et al.  Use of letrozole after aromatase inhibitor-based therapy in  postmenopausal breast cancer (NRG Oncology/NSABP B-42):  a randomised, double-blind, placebo-controlled, phase 3 trial  [J]. Lancet Oncol, 2019, 20(1): 88-99.
[25] METZGER FILHO O, GIOBBIE-HURDER A, MALLON E, et  al. Relative effectiveness of letrozole compared with tamoxifen  for patients with lobular carcinoma in the BIG 1-98 trial[J].  J Clin Oncol, 2015, 33(25): 2772-2779.
[26] PAN H C, GRAY R, BRAYBROOKE J, et al. 20-year risks of  breast-cancer recurrence after stopping endocrine therapy at 5  years[J]. N Engl J Med, 2017, 377(19): 1836-1846.
[27] BLUM J L, FLYNN P J, YOTHERS G, et al. Anthracyclines  in early breast cancer: the ABC trials-USOR 06-090, NSABP  B-46-I/USOR 07132, and NSABP B-49 (NRG oncology)[J].  J Clin Oncol, 2017, 35(23): 2647-2655.
[28] CARDOSO F, VAN'T VEER L J, BOGAERTS J, et al. 70-gene  signature as an aid to treatment decisions in early-stage breast  cancer[J]. N Engl J Med, 2016, 375(8): 717-729.
[29] EARLY BREAST CANCER TRIALISTS' COLLABORATIVE  GROUP (EBCTCG). Adjuvant bisphosphonate treatment in early  breast cancer: meta-analyses of individual patient data from  randomised trials[J]. Lancet, 2015, 386(10001): 1353-1361.
[30] EARLY BREAST CANCER TRIALISTS' COLLABORATIVE  GROUP (EBCTCG). Increasing the dose intensity of  chemotherapy by more frequent administration or sequential  scheduling: a patient-level meta-analysis of 37 298 women with  early breast cancer in 26 randomised trials[J]. Lancet, 2019,  393(10179): 1440-1452.
[31] LOIBL S, WEBER K E, TIMMS K M, et al. Survival analysis  of carboplatin added to an anthracycline/taxane-based  neoadjuvant chemotherapy and HRD score as predictor of  response-final results from GeparSixto[J]. Ann Oncol, 2018,  29(12): 2341-2347.
[32] MASUDA N, LEE S J, OHTANI S, et al. Adjuvant capecitabine  for breast cancer after preoperative chemotherapy[J]. N Engl  J Med, 2017, 376(22): 2147-2159.
[33] MOORE H C, UNGER J M, PHILLIPS K A, et al. Goserelin for  ovarian protection during breast-cancer adjuvant chemotherapy  [J]. N Engl J Med, 2015, 372(10): 923-932.
[34] NITZ U, GLUZ O, CLEMENS M, et al. West German  study PlanB trial: adjuvant four cycles of epirubicin and  cyclophosphamide plus docetaxel versus six cycles of docetaxel  and cyclophosphamide in HER2-negative early breast cancer  [J]. J Clin Oncol, 2019, 37(10): 799-808.
[35] SPARANO J A, GRAY R J, MAKOWER D F, et al. Adjuvant  chemotherapy guided by a 21-gene expression assay in breast  cancer[J]. N Engl J Med, 2018, 379(2): 111-121.
[36] PROWELL T M, BEAVER J A, PAZDUR R. Residual disease  after neoadjuvant therapy - developing drugs for high-risk early  breast cancer[J]. N Engl J Med, 2019, 380(7): 612-615.
[37] SPARANO J A, GRAY R J, RAVDIN P M, et al. Clinical and  genomic risk to guide the use of adjuvant therapy for breast  cancer[J]. N Engl J Med, 2019, 380(25): 2395-2405.
[38] EARL H M, HILLER L, VALLIER A L, et al. 6 versus 12  months of adjuvant trastuzumab for HER2-positive early breast  cancer (PERSEPHONE): 4-year disease-free survival results of  a randomised phase 3 non-inferiority trial[J]. Lancet, 2019,  393(10191): 2599-2612.
[39] MARTIN M, HOLMES F A, EJLERTSEN B, et al. Neratinib  after trastuzumab-based adjuvant therapy in HER2-positive  breast cancer (ExteNET): 5-year analysis of a randomised,  double-blind, placebo-controlled, phase 3 trial[J]. Lancet  Oncol, 2017, 18(12): 1688-1700.
[40] VON MINCKWITZ G, HUANG C S, MANO M S, et al.  Trastuzumab emtansine for residual invasive HER2-positive  breast cancer[J]. N Engl J Med, 2019, 380(7): 617-628.
[41] VON MINCKWITZ G, PROCTER M, DE AZAMBUJA E, et al.  Adjuvant pertuzumab and trastuzumab in early HER2-positive  breast cancer[J]. N Engl J Med, 2017, 377(2): 122-131.
[42] GIANNI L, PIENKOWSKI T, IM Y H, et al. Efficacy and safety  of neoadjuvant pertuzumab and trastuzumab in women with  locally advanced, inflammatory, or early HER2-positive breast  cancer (NeoSphere): a randomised multicentre, open-label,  phase 2 trial[J]. Lancet Oncol, 2012, 13(1): 25-32.
[43] MA F, LI Q, CHEN S S, et al. Phase I study and biomarker  analysis of pyrotinib, a novel irreversible pan-ErbB receptor  tyrosine kinase inhibitor, in patients with human epidermal  growth factor receptor 2-positive metastatic breast cancer[J].  J Clin Oncol, 2017, 35(27): 3105-3112.
[44] LANG G T, JIANG Y Z, SHI J X, et al. Characterization of the  genomic landscape and actionable mutations in Chinese breast  cancers by clinical sequencing[J]. Nat Commun, 2020,  11(1): 5679.
[45] JIANG Y Z, MA D, SUO C, et al. Genomic and transcriptomic  landscape of triple-negative breast cancers: subtypes and  treatment strategies[J]. Cancer Cell, 2019, 35(3): 428-440.  e5.
[46] LI J J, YU K D, PANG D, et al. Adjuvant capecitabine with  docetaxel and cyclophosphamide plus epirubicin for triplenegative breast cancer (CBCSG010): an open-label, randomized,  multicenter, phase III trial[J]. J Clin Oncol, 2020, 38(16):  1774-1784.
[47] YU K D, YE F G, HE M, et al. Effect of adjuvant paclitaxel and  carboplatin on survival in women with triple-negative breast  cancer: a phase 3 randomized clinical trial[J]. JAMA Oncol,  2020, 6(9): 1390-1396.
[48] WANG X, WANG S S, HUANG H, et al. Effect of capecitabine  maintenance therapy using lower dosage and higher frequency  vs observation on disease-free survival among patients with  early-stage triple-negative breast cancer who had received  standard treatment: the SYSUCC-001 randomized clinical trial  [J]. JAMA, 2021, 325(1): 50-58.
[49] HU X C, ZHANG J, XU B H, et al. Cisplatin plus gemcitabine  versus paclitaxel plus gemcitabine as first-line therapy for  metastatic triple-negative breast cancer (CBCSG006): a  randomised, open-label, multicentre, phase 3 trial[J]. Lancet  Oncol, 2015, 16(4): 436-446.
[50] ZHANG J, LIN Y, SUN X J, et al. Biomarker assessment of the  CBCSG006 trial: a randomized phase III trial of cisplatin plus  gemcitabine compared with paclitaxel plus gemcitabine as firstline therapy for patients with metastatic triple-negative breast  cancer[J]. Ann Oncol, 2018, 29(8): 1741-1747.
[51] LIN M X, CHEN Y, JIN Y Z, et al. Comparative overall survival  of CDK4/6 inhibitors plus endocrine therapy vs endocrine  therapy alone for hormone receptor-positive, HER2-negative  metastatic breast cancer[J]. J Cancer, 2020, 11(24): 71277136.
[52] FALLON M, GIUSTI R, AIELLI F, et al. Management of cancer  pain in adult patients: ESMO clinical practice guidelines[J].  Ann Oncol, 2018, 29(Suppl 4): iv166-iv191.
[53] ZHAO S, MA D, XIAO Y, et al. Molecular subtyping of triplenegative breast cancers by immunohistochemistry: molecular  basis and clinical relevance[J]. Oncologist, 2020, 25(10):  e1481-e1491.
[54] JIANG Y Z, LIU Y, XIAO Y, et al. Molecular subtyping and  genomic profiling expand precision medicine in refractory  metastatic triple-negative breast cancer: the FUTURE trial  [J]. Cell Res, 2021, 31(2): 178-186.
[55] ALBABTAIN H, ALWHAIBI M, ALBURAIKAN K, et al.  Quality of life and complementary and alternative medicine use  among women with breast cancer[J]. Saudi Pharm J, 2018,  26(3): 416-421.
[56] 林洪生, 刘 杰, 张 英. 《恶性肿瘤中医诊疗指南》的内  涵及其意义[J]. 中国肿瘤临床与康复, 2016, 23(3): 257260.  LIN H S, LIU J, ZHANG Y. Connotation and significance of  “Guidelines for Diagnosis and Treatment of Malignant Tumors  in Traditional Chinese Medicine”[J]. Chin J Clin Oncol  Rehabil, 2016, 23(3): 257-260.
[57] 陈前军, 裴晓华. 早期乳腺癌中医辨证内治专家共识[J].  现代中医临床, 2020, 27(3): 5-8.  CHEN Q J, PEI X H. Consensus on TCM syndrome  differentiation and internal therapy for early-stage breast cancer  [J]. Mod Chin Clin Med, 2020, 27(3): 5-8.
[58] 杨雯靖, 念家云, 杨国旺. 中西医结合治疗乳腺癌现状及展  望[J]. 北京中医药, 2020, 39(10): 1009-1013.  YANG W J, NIAN J Y, YANG G W. Present situation and  prospect of treating breast cancer with integrated traditional  Chinese and western medicine[J]. Beijing J Tradit Chin Med,  2020, 39(10): 1009-1013.
[59] 马 瑞, 张 丹, 林从尧. 小金丸、逍遥丸及乳癖散结胶  囊治疗乳腺增生的临床观察[J]. 现代中西医结合杂志,  2015, 24(2): 140-142.  MA R, ZHANG D, LIN C Y. Clinical observation of  Koganemaru, Xiaoyao Pill and Rubisanjie Capsule in the  treatment of mammary hyperplasia[J]. Mod J Integr Tradit  Chin West Med, 2015, 24(2): 140-142.
[60] 《乳腺癌HER检测指南版》编写组. 《乳腺癌HER2检测指  南(2019版)》[J]. 中华病理学杂志, 2019, 48(3): 169-175.  HER2 Detection Guidline for Breast Cancer (2019 Edition)  Writing Group. HER2 guideline for breast cancer (2019 Edition)  [J]. Chin J Pathol, 2019, 48(3): 169-175.
[61] 《乳腺癌新辅助治疗的病理诊断专家共识(2020版)》  编写组. 乳腺癌新辅助治疗的病理诊断专家共识(2020版)  [J]. 中华病理学杂志, 2020, 49(4): 296-304.  Expert Consensus on Pathological Diagnosis of Neoadjuvant  Therapy for Breast Cancer (2020 Edition) Writing Group. Expert  consensus on pathological diagnosis of neoadjuvant therapy for  breast cancer (2020 Edition)[J]. Chin J Pathol, 2020, 49(4):  296-304.
[62] 《乳腺癌雌、孕激素受体检测指南》编写组. 乳腺癌雌、  孕激素受体检测指南[J]. 中华病理学杂志, 2015, 44(4):  237-240.  Guidelines for Detection of Estrogen and Progesterone Receptors  in Breast Cancer Writing Group. Guidelines for detection of  estrogen and progesterone receptors in breast cancer[J].  Chin J Pathol, 2015, 44(4): 237-240.
[63] GOLDHIRSCH A, INGLE J N, GELBER R D, et al. Thresholds  for therapies: highlights of the St Gallen International Expert  Consensus on the primary therapy of early breast cancer 2009  [J]. Ann Oncol, 2009, 20(8): 1319-1329.
[64] GOLDHIRSCH A, WOOD W C, COATES A S, et al. Strategies  for subtypes: dealing with the diversity of breast cancer:  highlights of the St. Gallen international expert consensus on the  primary therapy of early breast cancer 2011[J]. Ann Oncol,2011, 22(8): 1736-1747.
[65] GOLDHIRSCH A, WINER E P, COATES A S, et al.  Personalizing the treatment of women with early breast cancer:  highlights of the St. Gallen international expert consensus on the  primary therapy of early breast cancer 2013[J]. Ann Oncol,  2013, 24(9): 2206-2223.
[66] WRIGHT M J, PARK J, FEY J V, et al. Perpendicular inked  versus tangential shaved margins in breast-conserving surgery:  does the method matter? [J]. J Am Coll Surg, 2007, 204(4):  541-549.
[67] ELSTON C W, ELLIS I O. Pathological prognostic factors in  breast cancer.I. The value of histological grade in breast  cancer: experience from a large study with long-term follow-up  [J]. Histopathology, 2002, 41(3a): 154-161.
[68] FRIERSON H F Jr, WOLBER R A, BEREAN K W, et al.  Interobserver reproducibility of the Nottingham modification  of the Bloom and Richardson histologic grading scheme for  infiltrating ductal carcinoma[J]. Am J Clin Pathol, 1995,  103(2): 195-198.
[69] HAMMOND M E, HAYES D F, DOWSETT M, et al. American  Society of Clinical Oncology/College of American Pathologists  guideline recommendations for immunohistochemical testing  of estrogen and progesterone receptors in breast cancer[J].  Arch Pathol Lab Med, 2010, 134(6): 907-922.
[70] DOWSETT M, NIELSEN T O, A’HERN R, et al. Assessment  of Ki-67 in breast cancer: recommendations from the  international Ki-67 in breast cancer working group[J]. J Natl  Cancer Inst, 2011, 103(22): 1656-1664.
[71] W O L F F A C , H A M M O N D M E , H I C K S D G , e t a l .  Recommendations for human epidermal growth factor receptor 2  testing in breast cancer: American Society of Clinical Oncology/  College of American Pathologists clinical practice guideline  update[J]. J Clin Oncol, 2013, 31(31): 3997-4013.
[72] SYMMANS W F, PEINTINGER F, HATZIS C, et al.  Measurement of residual breast cancer burden to predict  survival after neoadjuvant chemotherapy[J]. J Clin Oncol,  2007, 25(28): 4414-4422.
[73] OGSTON K N, MILLER I D, PAYNE S, et al. A new histological  grading system to assess response of breast cancers to primary  chemotherapy: prognostic significance and survival[J].  Breast, 2003, 12(5): 320-327.
[74] 水若鸿, 杨文涛. 乳腺癌Ki-67阳性指数的检测和评估  [J]. 中华病理学杂志, 2013, 42(6): 420-423.  SHUI R H, YANG W T. Detection and evaluation of Ki-67  positive index in breast cancer[J]. Chin J Pathol, 2013,  42(6): 420-423.
[75] LIN M X, JIN Y Z, YANG Z Y, et al. Determination and clinical  significance of bone pseudoprogression in hormone receptorpositive metastatic breast cancer[J]. Ther Adv Med Oncol,  2021, 13: 17588359211022881.
[76] ZHANG J F, LIN M X, JIN Y Z, et al. Cisplatin given at  three divided doses for three consecutive days in metastatic  breast cancer: an alternative schedule for one full dose with  comparable efficacy but less CINV and hypomagnesaemia[J].  Breast Cancer Res Treat, 2020, 182(3): 719-726.
[77] 《肿瘤病理诊断规范》项目组. 肿瘤病理诊断规范(乳腺癌)  [J]. 中华病理学杂志 2016, 45(8): 525-528.  The project team of Tumor Pathological Diagnosis Standard.  Diagnostic criteria for tumor pathology (breast cancer)[J].  Chin J Pathol, 2016, 45 (8): 525-528.
[78] 《 中 国 乳 腺 导 管 原 位 癌 病 理 诊 断 共 识 ( 2 0 2 2 版 ) 》  编写组. 中国乳腺导管原位癌病理诊断共识(2022  版)[J]. 中华病理学杂志, 2022, 51(9): 812-818.  The Writing Team of the Chinese Consensus on Pathological  Diagnosis of Breast Ductal Carcinoma in situ (2022 Edition).  Chinese consensus on pathological diagnosis of ductal  carcinoma in situ of the breast (2022 edition) [J]. Chin J  Pathol, 2022, 51 (9): 812-818.
[79] 杨昭志, 孟 晋, 马金利, 等. 早期乳腺癌术后靶区勾画共识  [J]. 中国癌症杂志, 2019, 29(9): 753-760.  YANG Z Z, MENG J, MA J L, et al. Early stage breast cancer  postoperative target volume contouring[J]. China Oncol,  2019, 29(9)753-760
[80] WOLFF A C, ELIZABETH HALE HAMMOND M, ALLISON  K H, et al. Human epidermal growth factor receptor 2 testing in  breast cancer: American Society of Clinical Oncology/College  of American Pathologists clinical practice guideline focused  update[J]. J Clin Oncol, 2018, 36(20): 2105-2122.
[81] WOLFF A C, SOMERFIELD M R, DOWSETT M, et al. Human  epidermal growth factor receptor 2 testing in breast cancer:  ASCO-College of American Pathologists guideline update[J].  J Clin Oncol, 2023, 41(22): 3867-3872.
[82] TARANTINO P, VIALE G, PRESS M F, et al. ESMO expert  consensus statements (ECS) on the definition, diagnosis, and  management of HER2-low breast cancer[J]. Ann Oncol,  2023, 34(8): 645-659.
[83] SHI F, LIANG Z, ZHANG Q, et al. The performance of onestep nucleic acid amplification assay for intraoperative detection  of sentinel lymph node macrometastasis in breast cancer: an  updated meta-analysis[J]. Breast, 2018, 39: 39-45.
[84] HUXLEY N, JONES-HUGHES T, COELHO H, et al.  Intraoperative tests (RD-100i OSNA system and Metasin test)  for detecting sentinel lymph node metastases in breast cancer  [J]. Health Technol Assess, 2015, 19(2): V-XXV.
[85] BUNDRED J R, MICHAEL S, STUART B, et al. Margin status  and survival outcomes after breast cancer conservation surgery:  prospectively registered systematic review and meta-analysis  [J]. BMJ, 2022, 378: e070346.
[86] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌  诊治指南与规范(2021年版)[J]. 中国癌症杂志, 2021,  31(10): 954-1040.  The Society of Breast Cancer China Anti-Cancer Association.  Guidelines for breast cancer diagnosis and treatment by China  Anti-cancer Association (2021 edition)[J]. China Oncol,  2021, 31(10): 954-1040.